Compare RVYL & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVYL | GTBP |
|---|---|---|
| Founded | 2007 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 8.8M |
| IPO Year | 2008 | 2016 |
| Metric | RVYL | GTBP |
|---|---|---|
| Price | $7.81 | $0.39 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.2K | ★ 1.3M |
| Earning Date | 04-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,131,000.00 | N/A |
| Revenue This Year | $770.54 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.14 | $0.26 |
| 52 Week High | $8.55 | $3.73 |
| Indicator | RVYL | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 67.46 | 51.65 |
| Support Level | $5.00 | $0.26 |
| Resistance Level | $8.55 | $0.44 |
| Average True Range (ATR) | 0.65 | 0.04 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 96.06 | 55.53 |
Ryvyl Inc is a financial technology company that provides payment acceptance and disbursement solutions, mainly enabling merchants to process credit card transactions through BIN sponsorship arrangements with acquiring banks and payment processors, where it operates as an intermediary performing functions such as merchant underwriting, onboarding, risk monitoring, and customer support. The company also offers its internally developed NEMS Core platform, which facilitates automated inbound and outbound disbursements through a modular workflow system.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.